Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

Loredana Santo, MD, Teru Hideshima, MD, PhD, Diana Cirstea, MD, Madhavi L Bandi, PhD, Erik A Nelson, PhD, Hiroshi Ikeda, MD, Sonia Vallet, MD, Samantha Pozzi, MD, Kishan Patel, Gullu Gorgun, PhD, Naoya Mimura, MD, Claire Fabre, MD, Yiguo Hu, PhD, Dharminder Chauhan, PhD, Matthew S Squires, PhD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Noopur Raje, MD

Blood (2010) 116 (21): 2994.

https://doi.org/10.1182/blood.V116.21.2994.2994

Published: 2010

Journal Articles

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Thomas P. Miller, MD, Matthew S Squires, PhD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3930.

https://doi.org/10.1182/blood.V116.21.3930.3930

Published: 2010

Journal Articles

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

Shamim Lotfi, MS, Aarthi Jayanthan, BS, Victor A. Lewis, MD, Greg Guilcher, MD, Matthew S Squires, PhD, Todd Cooper, DO, Aru Narendran, MD., Ph.D

Blood (2009) 114 (22): 3078.

https://doi.org/10.1182/blood.V114.22.3078.3078

Published: 2009

Journal Articles

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

Ruriko Tanaka, MMSc, Matthew S Squires, PhD, Shinya Kimura, MD, PhD, Asumi Yokota, MMSc, Kirsty Mallett, PhD, Tomoko Smyth, PhD, Neil T Thompson, PhD, Rina Nagao, Takahiro Yamauchi, MD, Takashi Ushiki, MD, John F Lyons, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 1104.

https://doi.org/10.1182/blood.V112.11.1104.1104

Published: 2008

Journal Articles

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

Matthew S. Squires, PhD, Ruth E. Feltell, BSc, Victoria Lock, Donna M. Smith, PhD, Jon E. Lewis, Jacqueline Higgins, Murray Yule, MD, Neil T. Thompson, PhD, Laurence Cooke, Kimiko D. Croce, Wenqing Qi, John F. Lyons, PhD, Daruka Mahadevan

Blood (2007) 110 (11): 3127.

https://doi.org/10.1182/blood.V110.11.3127.3127

Published: 2007

Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green

Blood (2007) 110 (11): 3537.

https://doi.org/10.1182/blood.V110.11.3537.3537

Published: 2007

NARROW

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Email alerts

ASH Publications

American Society of Hematology

AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

AT9283, A Novel Aurora Kinase/Jak2 Inhibitor Demonstrates Activity against Refractory Infant Leukemia Cells: Studies On Growth Inhibition, Biological Correlates, Drug Synergy and Effects On Leukemia Stem-Like Cells.

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only